Vorinostat in Treating Patients With Metastatic Melanoma of the Eye
Status:
Recruiting
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well vorinostat works in treating patients with melanoma of
the eye that has spread to other parts of the body (metastatic). Vorinostat may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)
Collaborators:
Institut Curie Paris Memorial Sloan Kettering Cancer Center Moffitt Cancer Center P2C